Recent Updates
Recently added Catalysts
VKTX Positive Sentiment

Treatment with Oral VK2735 Results in Significant Weight Loss: The Randomized, Placebo-Controlled, Dose-Finding, VENTURE-Oral Study

Monday, May 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The VENTURE-Oral study demonstrated that VK2735, an oral treatment, resulted in significant weight loss among participants. This randomized, placebo-controlled trial highlights the potential of VK2735 as an effective option for obesity management. The findings could have a substantial impact on future obesity treatments.
Price reaction · baseline $31.72 (2026-05-11 close) · hit after-hours · 1 other VKTX headline(s) in the window, move may be shared
day 0 close · peak
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • VK2735 shows significant weight loss results in the VENTURE-Oral study.
  • The study is randomized and placebo-controlled, enhancing credibility.
  • Positive implications for obesity treatment with VK2735.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

• About Management Board of Directors Careers
• Pipeline Overview VK2735 VK3019 VK2809 VK0214 VK5211 Publications
• Investors Overview Stock Information Stock Chart Historical Price Lookup News & Events Press Releases Webcasts SEC Filings Analyst Coverage Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition Shareholder Services Information Request E-mail Alerts Investor Relations Contacts Corporate Presentation
• Contact
• Management
• Board of Directors
• Careers
• Overview
• VK2735
• VK3019
• VK2809
• VK0214
• VK5211
• Publications
• Overview
• Stock Information Stock Chart Historical Price Lookup
• News & Events Press Releases Webcasts
• SEC Filings
• Analyst Coverage
• Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition
• Shareholder Services Information Request E-mail Alerts Investor Relations Contacts
• Corporate Presentation
• Stock Chart
• Historical Price Lookup
• Press Releases
• Webcasts
• Governance Highlights
• Mangement
• Board of Directors
• Committee Composition
• Information Request
• E-mail Alerts
• Investor Relations Contacts

Frequently Asked Questions

What is VK2735?

VK2735 is an oral treatment being studied for its effects on weight loss.

What was the focus of the VENTURE-Oral study?

The VENTURE-Oral study focused on evaluating the weight loss efficacy of VK2735.

How was the VENTURE study conducted?

The study was randomized and placebo-controlled to ensure reliable results.

What are the implications of VK2735's results?

The results suggest VK2735 could be a promising option for obesity treatment.

ShareAdd on Google
Tags: VKTX Viatris Investor Conferences Healthcare VK2735 weight loss VENTURE study obesity treatment
Last updated: May 11, 2026

Biotech snapshot

Cash runway
$502M liquidity · $42M/mo burn
~11 mo
Medium dilution risk
Lead asset
VK2735Phase 3
Weight Loss →

Catalyst track record

+53%
best trade around VKTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for VKTX.

See every catalyst's timing & PoA →